KR102923666B1 - 푸로세미드의 농축된 액체 제약 제제 및 그의 투여 방법 - Google Patents

푸로세미드의 농축된 액체 제약 제제 및 그의 투여 방법

Info

Publication number
KR102923666B1
KR102923666B1 KR1020217027628A KR20217027628A KR102923666B1 KR 102923666 B1 KR102923666 B1 KR 102923666B1 KR 1020217027628 A KR1020217027628 A KR 1020217027628A KR 20217027628 A KR20217027628 A KR 20217027628A KR 102923666 B1 KR102923666 B1 KR 102923666B1
Authority
KR
South Korea
Prior art keywords
liquid pharmaceutical
pharmaceutical formulation
pharmaceutically acceptable
furosemide
benzyl alcohol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020217027628A
Other languages
English (en)
Korean (ko)
Other versions
KR20210150360A (ko
Inventor
알프레도 그로시
브릿 코스트라바
올라토쿰보 오. 루카 오군레이에
섀넌 테리
프란시스쿠스 코펜하겐
Original Assignee
에스씨파마슈티칼스 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에스씨파마슈티칼스 인코포레이티드 filed Critical 에스씨파마슈티칼스 인코포레이티드
Priority to KR1020267003410A priority Critical patent/KR20260036554A/ko
Publication of KR20210150360A publication Critical patent/KR20210150360A/ko
Application granted granted Critical
Publication of KR102923666B1 publication Critical patent/KR102923666B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • A61M5/142—Pressure infusion, e.g. using pumps
    • A61M5/14244—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body
    • A61M5/14248—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body of the skin patch type

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
KR1020217027628A 2019-01-31 2020-01-30 푸로세미드의 농축된 액체 제약 제제 및 그의 투여 방법 Active KR102923666B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020267003410A KR20260036554A (ko) 2019-01-31 2020-01-30 푸로세미드의 농축된 액체 제약 제제 및 그의 투여 방법

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962799215P 2019-01-31 2019-01-31
US62/799,215 2019-01-31
PCT/US2020/015799 WO2020160210A1 (en) 2019-01-31 2020-01-30 Concentrated liquid pharmaceutical formulations of furosemide and methods of administering the same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020267003410A Division KR20260036554A (ko) 2019-01-31 2020-01-30 푸로세미드의 농축된 액체 제약 제제 및 그의 투여 방법

Publications (2)

Publication Number Publication Date
KR20210150360A KR20210150360A (ko) 2021-12-10
KR102923666B1 true KR102923666B1 (ko) 2026-02-06

Family

ID=69740677

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020217027628A Active KR102923666B1 (ko) 2019-01-31 2020-01-30 푸로세미드의 농축된 액체 제약 제제 및 그의 투여 방법
KR1020267003410A Pending KR20260036554A (ko) 2019-01-31 2020-01-30 푸로세미드의 농축된 액체 제약 제제 및 그의 투여 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020267003410A Pending KR20260036554A (ko) 2019-01-31 2020-01-30 푸로세미드의 농축된 액체 제약 제제 및 그의 투여 방법

Country Status (15)

Country Link
US (10) US11998555B2 (https=)
EP (1) EP3917495A1 (https=)
JP (3) JP7465881B2 (https=)
KR (2) KR102923666B1 (https=)
CN (2) CN118319852A (https=)
AU (2) AU2020214314B2 (https=)
BR (1) BR112021014637A2 (https=)
CA (1) CA3128033A1 (https=)
EA (1) EA202192129A1 (https=)
IL (2) IL285073B2 (https=)
MA (1) MA54865A (https=)
MX (2) MX2021009084A (https=)
PH (1) PH12021551811A1 (https=)
SG (1) SG11202108280RA (https=)
WO (1) WO2020160210A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2981258T (pt) * 2013-04-05 2020-10-19 Scpharmaceuticals Inc Formulações farmacêuticas para administração subcutânea de furosemida
PH12021551811A1 (en) 2019-01-31 2022-03-21 Scpharmaceuticals Inc Concentrated liquid pharmaceutical formulations of furosemide and methods of administering the same
JP2024512650A (ja) * 2021-04-02 2024-03-19 エスシーファーマシューティカルズ インコーポレイテッド フロセミドの皮下注入
EP4648761A1 (en) * 2023-01-09 2025-11-19 scPharmaceuticals Inc. Methods of treatment using loop diuretics

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160051507A1 (en) * 2013-04-05 2016-02-25 Scpharmaceuticals Inc. Pharmaceutical Formulations for Subcutaneous Administration of Furosemide

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2134671A1 (de) 1971-07-08 1973-01-25 Josef Dipl Chem Dr Rer N Klosa Pharmazeutische praeparate
US4663348A (en) 1985-07-02 1987-05-05 Warner-Lambert Co. Furosemide salts and pharmaceutical preparations thereof
US4698361A (en) 1986-05-28 1987-10-06 Schiena Michele G Di Tris-chydroxymethyl) aminomethane salt of 4-chloro-N-furfuryl-5-sulfamoyl anthranilic acid and diuretic compositions containing the same
DE3623620A1 (de) 1986-07-12 1988-01-21 Boehringer Mannheim Gmbh Spritzfertige, waessrige, alkalische injektionsloesungen von torasemid und verfahren zu ihrer herstellung
US4853439A (en) 1987-10-09 1989-08-01 Gaf Corporation Water-soluble complexes of water-insoluble organic compounds
EP0416232B1 (en) * 1989-08-21 1995-08-16 American Cyanamid Company Stable injectable pharmaceutical formulation for folic acid and leucovorin salts and method
WO1992021769A1 (en) 1991-05-30 1992-12-10 Abbott Laboratories Reagents containing a nonspecific binding blocker in ion-capture binding assays
US5633240A (en) 1994-09-01 1997-05-27 Academic Pharmaceuticals Parenteral solutions containing metolazone
IT1283608B1 (it) * 1996-04-17 1998-04-22 Ricerche Di Schiena Snc Di Dr Composizione farmaceutica per la terapia orale diuretica ed antiipertensiva.
CN1068778C (zh) 1998-05-15 2001-07-25 赵超英 救治用的药物组合物及其制备方法
ATE409280T1 (de) 2005-12-28 2008-10-15 Sensile Pat Ag Mikropumpe
MX2009000385A (es) 2006-07-12 2009-04-06 Univ Tennessee Res Foundation Acil-anilidas sustituidas y metodos de uso de las mismas.
EP2022518A1 (en) 2007-08-07 2009-02-11 Sensile Pat AG Modular drug delivery device for administering discrete doses of a medicament
US7923447B2 (en) 2008-03-17 2011-04-12 Academic Pharmaceuticals Incorporated Parenteral solutions containing metolazone
CA2724540C (en) 2008-05-16 2014-07-08 Corthera, Inc. Treating dyspnea associated with acute heart failure with relaxin
EP2334302B1 (en) 2008-09-09 2018-03-21 Cima Labs Inc DOSAGE FORMS FOR ACTIVE INGREDIENTS THAT ARE LOWLY IONIZABLE
US20110060280A1 (en) 2009-09-04 2011-03-10 Sean Caffey Adhesive skin patch with pump for subcutaneous drug delivery
AU2012325801B2 (en) 2011-10-19 2016-05-12 Mercator Medsystems, Inc. Localized modulation of tissues and cells to enhance therapeutic effects including renal denervation
CN103371967A (zh) * 2012-04-17 2013-10-30 上海禾丰制药有限公司 呋塞米注射液及其制剂工艺
EP3682902A1 (en) * 2012-05-18 2020-07-22 Luoda Pharma Limited Liquid formulation
ES3041602T3 (en) 2018-12-10 2025-11-13 Sq Innovation Ag Pharmaceutical compositions of furosemide and uses thereof
US12397005B2 (en) 2019-01-04 2025-08-26 Sq Innovation Ag Pharmaceutical compositions of torsemide and uses thereof
US11246851B2 (en) 2019-01-04 2022-02-15 Sq Innovation Ag Pharmaceutical compositions of furosemide and uses thereof
PH12021551811A1 (en) 2019-01-31 2022-03-21 Scpharmaceuticals Inc Concentrated liquid pharmaceutical formulations of furosemide and methods of administering the same

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160051507A1 (en) * 2013-04-05 2016-02-25 Scpharmaceuticals Inc. Pharmaceutical Formulations for Subcutaneous Administration of Furosemide

Also Published As

Publication number Publication date
IL323325A (en) 2025-11-01
US20240299419A1 (en) 2024-09-12
JP2025170052A (ja) 2025-11-14
US20220096500A1 (en) 2022-03-31
KR20210150360A (ko) 2021-12-10
US20220168323A1 (en) 2022-06-02
US20240316071A1 (en) 2024-09-26
CN118319852A (zh) 2024-07-12
CN113747881A (zh) 2021-12-03
US11998555B2 (en) 2024-06-04
US12491193B2 (en) 2025-12-09
MX2021009084A (es) 2021-10-26
US12491194B2 (en) 2025-12-09
IL285073B1 (en) 2025-10-01
IL285073A (en) 2021-09-30
US11559535B2 (en) 2023-01-24
JP2024086756A (ja) 2024-06-28
MX2023012741A (es) 2024-02-27
AU2020214314B2 (en) 2025-09-18
BR112021014637A2 (pt) 2021-09-21
US20230277558A1 (en) 2023-09-07
EA202192129A1 (ru) 2021-10-19
AU2025283539A1 (en) 2026-01-15
WO2020160210A1 (en) 2020-08-06
JP7738696B2 (ja) 2025-09-12
IL285073B2 (en) 2026-02-01
CN113747881B (zh) 2024-05-14
US20220378806A1 (en) 2022-12-01
US20240325411A1 (en) 2024-10-03
US20220378805A1 (en) 2022-12-01
SG11202108280RA (en) 2021-08-30
KR20260036554A (ko) 2026-03-17
PH12021551811A1 (en) 2022-03-21
US12491195B2 (en) 2025-12-09
CA3128033A1 (en) 2020-08-06
US12048709B2 (en) 2024-07-30
JP7465881B2 (ja) 2024-04-11
US11497755B2 (en) 2022-11-15
JP2022518900A (ja) 2022-03-17
US11571434B2 (en) 2023-02-07
US20240307417A1 (en) 2024-09-19
EP3917495A1 (en) 2021-12-08
US12491196B2 (en) 2025-12-09
US20240316070A1 (en) 2024-09-26
US12491197B2 (en) 2025-12-09
AU2020214314A1 (en) 2021-08-19
MA54865A (fr) 2022-05-04

Similar Documents

Publication Publication Date Title
KR102923666B1 (ko) 푸로세미드의 농축된 액체 제약 제제 및 그의 투여 방법
KR20250099120A (ko) 루프 이뇨제의 액상 약학적 제형 및 이의 투여 방법
EA046008B1 (ru) Концентрированные жидкие фармацевтические составы фуросемида и способы их введения
KR20260035797A (ko) 루프 이뇨제를 사용한 치료 방법

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D22-EXM-PE0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

A16 Divisional, continuation or continuation in part application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A16-DIV-PA0104 (AS PROVIDED BY THE NATIONAL OFFICE)

F11 Ip right granted following substantive examination

Free format text: ST27 STATUS EVENT CODE: A-2-4-F10-F11-EXM-PR0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

U12 Designation fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U12-OTH-PR1002 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

Q13 Ip right document published

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE)